inotersen
Selected indexed studies
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. (N Engl J Med, 2018) [PMID:29972757]
- Inotersen: First Global Approval. (Drugs, 2018) [PMID:30120737]
- Inotersen. (, 2026) [PMID:35201734]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (2023) pubmed
- Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. (2024) pubmed
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. (2018) pubmed
- Inotersen: First Global Approval. (2018) pubmed
- Inotersen. (2026) pubmed
- Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. (2019) pubmed
- Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis. (2020) pubmed
- Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. (2019) pubmed
- Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. (2019) pubmed
- PMID:40892952 (2019) pubmed